MoonLake Immunotherapeutics (NASDAQ:MLTX) Given Consensus Recommendation of “Hold” by Brokerages

Shares of MoonLake Immunotherapeutics (NASDAQ:MLTX) have been given a consensus recommendation of “Hold” by the sixteen brokerages that are currently covering the company, Marketbeat Ratings reports. Five analysts have rated the stock with a sell rating, four have given a hold rating and seven have issued a buy rating on the company. The average twelve-month price target among analysts that have issued a report on the stock in the last year is $25.7692.

A number of brokerages have weighed in on MLTX. BTIG Research reissued a “buy” rating and issued a $24.00 price target on shares of MoonLake Immunotherapeutics in a report on Monday, February 9th. The Goldman Sachs Group lowered shares of MoonLake Immunotherapeutics from a “neutral” rating to a “sell” rating and upped their price objective for the company from $8.00 to $10.00 in a research report on Wednesday, January 14th. Zacks Research downgraded MoonLake Immunotherapeutics from a “hold” rating to a “strong sell” rating in a research report on Tuesday, January 20th. Oppenheimer reissued an “outperform” rating and set a $30.00 target price on shares of MoonLake Immunotherapeutics in a research report on Thursday, November 6th. Finally, Citigroup cut MoonLake Immunotherapeutics from a “neutral” rating to a “sell” rating in a report on Wednesday, October 29th.

Insiders Place Their Bets

In other MoonLake Immunotherapeutics news, insider Kristian Reich sold 130,000 shares of the business’s stock in a transaction on Monday, December 8th. The shares were sold at an average price of $15.08, for a total value of $1,960,400.00. Following the sale, the insider owned 72,908 shares of the company’s stock, valued at $1,099,452.64. The trade was a 64.07% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, CEO Da Silva Jorge Santos sold 130,000 shares of the stock in a transaction on Monday, December 8th. The shares were sold at an average price of $15.08, for a total transaction of $1,960,400.00. Following the completion of the transaction, the chief executive officer owned 2,948,577 shares of the company’s stock, valued at approximately $44,464,541.16. This represents a 4.22% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 402,908 shares of company stock valued at $5,987,162 over the last 90 days. 12.05% of the stock is currently owned by corporate insiders.

Institutional Trading of MoonLake Immunotherapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in MLTX. Kestra Advisory Services LLC acquired a new position in MoonLake Immunotherapeutics in the fourth quarter worth about $26,000. FNY Investment Advisers LLC bought a new stake in shares of MoonLake Immunotherapeutics in the 3rd quarter valued at approximately $28,000. Bank of America Corp DE raised its holdings in shares of MoonLake Immunotherapeutics by 64.7% in the 3rd quarter. Bank of America Corp DE now owns 4,532 shares of the company’s stock worth $32,000 after buying an additional 1,781 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank raised its holdings in shares of MoonLake Immunotherapeutics by 115.0% in the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 5,919 shares of the company’s stock worth $42,000 after buying an additional 3,166 shares in the last quarter. Finally, Covestor Ltd bought a new position in shares of MoonLake Immunotherapeutics during the 3rd quarter worth approximately $46,000. Institutional investors own 93.85% of the company’s stock.

MoonLake Immunotherapeutics Stock Up 1.0%

MLTX opened at $15.77 on Monday. The business has a 50 day moving average of $14.92 and a 200-day moving average of $25.31. The stock has a market capitalization of $1.01 billion, a price-to-earnings ratio of -4.75 and a beta of 1.20. The company has a current ratio of 8.50, a quick ratio of 8.50 and a debt-to-equity ratio of 0.25. MoonLake Immunotherapeutics has a 1-year low of $5.95 and a 1-year high of $62.75.

MoonLake Immunotherapeutics Company Profile

MoonLake Immunotherapeutics is a clinical-stage biopharmaceutical company focused on the discovery and development of novel immunomodulatory therapies for autoimmune and inflammatory diseases. The company leverages a proprietary platform designed to selectively modulate key immune cell populations, aiming to restore immune balance and reduce tissue damage with targeted biologic candidates.

Its lead asset, MLTX101, is a recombinant immune cell modulator in clinical development for myositis, including inclusion body myositis and dermatomyositis.